<DOC>
	<DOCNO>NCT01511289</DOCNO>
	<brief_summary>In study , efficacy safety two radotinib dos , 300 mg twice daily 400 mg twice daily , compare imatinib 400 mg daily newly diagnose patient Philadelphia chromosome-positive ( Ph+ ) Chronic Myelogenous Leukemia chronic phase ( CML-CP ) .</brief_summary>
	<brief_title>Radotinib Versus Imatinib Newly Diagnosed Philadelphia Chromosome Chronic Myeloid Leukemia Chronic Phase Patients</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Hematologic Diseases</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<mesh_term>Bone Marrow Diseases</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Patients confirm diagnosis chronic phase CML within last 3 month Patients cytogenetically confirm Ph positive CML early chronic phase Patients Philadelphia chromosome negative BCRABL positive CML Patients use imatinib 8 day longer study entry Patients treat targeted anticancer therapy , except Hydrea Agrylin , inhibit growth leukemic cell Patients impaired cardiac function Cytologically confirm CNS involvement Severe uncontrolled chronic medical condition Other significant congenital acquire bleed disorder related underlying leukemia Patients major surgery within 4 week prior study entry recover side effect surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Radotinib</keyword>
	<keyword>CML-CP</keyword>
	<keyword>Chronic Myeloid Leukemia , chronic phase</keyword>
</DOC>